ImmPACT Bio Announces Opening of California-Based GMP Facility for Clinical Production of IMPT-314, a CD19/CD20 CAR T Therapy for B-Cell Malignancies and Autoimmune Diseases

State-of-the-art 21,500 square foot facility integrates research, development, manufacturing, and testing for end-to-end autologous CAR T-cell therapy production Dosing of first patient in Phase 1/2 trial evaluating IMPT-314 in aggressive B-cell lymphoma expected Q2 2023 WEST HILLS, Calif….